Antibodies in Repeated Influenza Vaccination (ARIVA) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-01

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy.

The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159

Influenza

COMPLETED PHASE4

Immunogenicity Study of the Influenza Vaccine in Adults

NCT00258934

Orthomyxoviridae Infections Influenza

COMPLETED PHASE2

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

NCT01633749

Prophylaxis of Influenza

COMPLETED PHASE3

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

NCT00318149

Influenza

COMPLETED PHASE2

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

NCT04794829

Influenza COVID-19

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccine Response Impaired

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Influenza Vaccination

Only subjects vaccinated against influenza will be enrolled. The study itself is observational

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* influenza vaccination (QIIV) independent of the study
* age \>18 yo

Exclusion Criteria

* no vaccination
* current acute illness

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christoph Berger

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph T Berger, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Basel, Medical Outpatient Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARIVA_me17Berger

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

NCT02126761 COMPLETED PHASE1

Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients

NCT01022905 COMPLETED PHASE4

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

NCT00644059 COMPLETED PHASE3

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

NCT01885117 COMPLETED PHASE3

Immune Response to Influenza Vaccination

NCT00551837 COMPLETED

Immune Response Study of Influenza Vaccine

NCT01310374 COMPLETED

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

NCT00311480 COMPLETED PHASE2

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

NCT02267733 COMPLETED PHASE1

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

NCT00841763 COMPLETED PHASE3

A/H5N1in Adult - Aventis

NCT00115986 COMPLETED PHASE1/PHASE2

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

NCT00970177 COMPLETED PHASE3

Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe

NCT00479921 COMPLETED PHASE3

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

NCT00457509 COMPLETED PHASE1

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

NCT01002040 COMPLETED PHASE4

T and B Cell Response to Avian Flu Vaccine

NCT00337896 COMPLETED

Influenza Vaccine in HIV Study

NCT02632578 COMPLETED

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection

NCT05110911 ACTIVE_NOT_RECRUITING

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

NCT03061955 COMPLETED

A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects

NCT02037282 WITHDRAWN PHASE1

Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

NCT01404182 COMPLETED PHASE4

A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

NCT00848887 COMPLETED PHASE1

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

NCT01342796 COMPLETED PHASE2

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580 COMPLETED PHASE2

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

NCT01146015 COMPLETED PHASE3

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

NCT01651104 COMPLETED PHASE2